NEJM: Ipale net treatment of cardiovascular and kidney outcomes in patients with heart failure.

Glucose-glucose co-transport protein 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure, with or without diabetes.
need more evidence of the role of these drugs in heart failure patients, including those with significantly lower blood test scores.
, in a recent study published in the top medical journal NEJM, in addition to the recommended treatment, the researchers randomly assigned 3,730 patients with LEVEL II, III or IV heart failure and no more than 40 percent of patients with a blood test score of less than 40 percent to receive ipale net (10 mg once a day) or placebo treatment.
outcome of the study was a combination of cardiovascular death or hospitalization due to increased heart failure.
during the 16-month mid-level follow-up period, 361 (19.4%) of the 1863 patients in the Ipale net group and 462 patients (462. 7%) had a major outcome event (the risk of hospitalization for cardiovascular death or heart failure was 0.75; 95% confidence interval was 0.65 to 0.86; P.lt;0.001).
with or without diabetes, the effects of Ipale net on major outcomes were consistent in patients.
total number of hospitalizations for heart failure in the Ipale net group was lower than in the placebo group (risk ratio was 0.70; 95% CI was 0.58 to 0.85; P.lt;0.001).
The estimated annual rate of decline in renal cystic filtration was slower than that of the placebo group (0.55 vs. 2.28 ml per minute per 1.73 m2 surface area per year), and the risk of severe renal outcomes was lower in patients in the Ipale net treatment group.
reported more frequently for the treatment of reproductive tract infections in Ipale.
thus, the risk of cardiovascular death or hospitalization for heart failure was lower in patients with heart failure recommended by the guidelines, regardless of diabetes.
.